New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
12:01 EDTGILD, BTUStocks with call strike movement; BTU GILD
Peabody (BTU) September 22 call option implied volatility increased 4% to 34, Gilead (GILD) August 90 option implied volatility decreased 2% to 30 according to IVolatility.
News For BTU;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 27, 2015
09:17 EDTBTUOn The Fly: Pre-market Movers
HIGHER: Silicon Image (SIMG), up 23% after signing agreement to be acquired by Lattice Semiconductor (LSCC)... USA Technologies (USAT), up 5% following nationwide roll-out of new Apple Pay points... TE Connectivity (TEL), up 3.9% following a Wall Street Journal report that the company is close to a deal with Commscope (COMM)... Select Comfort (SCSS), up 1% after being upgraded to Buy from Hold at Stifel. DOWN AFTER EARNINGS: Microsoft (MSFT), down 8.2%... Caterpillar (CAT), down 7.8%... Packaging Corp (PKG), down 8.3%... Peabody Energy (BTU), down 5.3%... Freeport-McMoRan (FCX), down 5.7%... Polaris Industries (PII), down 2.1%... United Technologies (UTX), down 2.3%... Procter & Gamble (PG), down 2.6%.
08:53 EDTGILDGilead February weekly volatility elevated into Q4 and outlook
Subscribe for More Information
08:44 EDTBTUPeabody lowers February dividend to 0.25c per share from 8.5c
As part of a comprehensive program to manage cash and liquidity, Peabody announced earlier that it has reduced the February quarterly dividend to 0.25c per share. "Peabody's Board of Directors will continue to evaluate the appropriate dividend level on a quarterly basis. Given market conditions in recent years, Peabody has taken aggressive actions to reduce operating and corporate costs, lower capital spending and complete asset sales to maintain adequate levels of cash and liquidity. Over the next two years, Peabody has nearly $1B in annual cash payments associated with debt service, capital investments, Powder River Basin reserve installments and health benefit trust payments. The annual payments related to the final Powder River Basin reserve installments and health benefit trust payments amount to approximately $350M of the total, and end within two years," the company said.
08:10 EDTBTUPeabody sees Q1 adjusted EPS (39c)-(32c), consensus (24c)
Sees Q1 adjusted EBITDA $160M-$200M. Compared with the fourth quarter of 2014, first quarter 2015 targets reflect the above mentioned annual guidance, lower seaborne thermal coal pricing, expected lower Resource Management contributions and two Australian longwall moves.
08:09 EDTBTUPeabody sees FY15 sales volumes 245M-265M tons
Subscribe for More Information
08:06 EDTBTUPeabody sees 2015 metallurgical coal import demand increases to outpace supply
Subscribe for More Information
08:05 EDTBTUPeabody says 2014 was a 'turbulent year for coal markets'
Subscribe for More Information
08:04 EDTBTUPeabody reports Q4 EPS ($1.21), consensus (35c)
Subscribe for More Information
January 26, 2015
16:01 EDTGILDOptions Update; January 26, 2015
iPath S&P 500 VIX Short-Term Futures down 1.47 to 30.63. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX X MSFT BP GILD according to Track Data.
15:40 EDTBTUNotable companies reporting before tomorrow's open
Subscribe for More Information
13:01 EDTGILDGilead, EnvisionRx sign exclusive agreement for Sovaldi, Harvoni availability
Subscribe for More Information
11:43 EDTBTUPeabody upgraded to In-Line from Underperform at Imperial Capital
Subscribe for More Information
11:36 EDTBTUPeabody upgraded to In-Line from Underperform at Imperial Capital
Subscribe for More Information
11:00 EDTGILDMylan expands Hepatitis C licensing agreement with Gilead
Mylan (MYL) announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences (GILD) to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816, once approved, in 91 developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes. A pan-genotypic therapeutic option is particularly important for developing countries, where genotype testing is often unreliable or not readily available. This agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead in September 2014, which grants Mylan the non-exclusive rights to manufacture and distribute sofosbuvir and ledipasvir/sofosbuvir in 91 developing countries. Mylan also partners with Gilead on expanding access to high quality, affordable antiretrovirals for the treatment of HIV/AIDS in India and other developing countries.
09:49 EDTGILDActive equity options trading
Subscribe for More Information
05:11 EDTGILDGilead expands hepatitis C generic licensing agreements
Subscribe for More Information
January 23, 2015
09:35 EDTGILDGilead mentioned cautiously at Cleveland Research
Subscribe for More Information
January 22, 2015
10:12 EDTBTUPeabody names Glenn Kellow President and President-elect
Subscribe for More Information
January 20, 2015
16:00 EDTGILDOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
09:38 EDTGILDActive equity options trading
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use